FWD1802 Updates at ESMO 2025
The European Society for Medical Oncology (ESMO) 2025 Annual Meeting took place in Berlin, Germany from Oct 17 - Oct 21. The conference showcased numerous frontier clinical research findings and attracted renowned experts and professors from around the world. Multiple cutting-edge research findings in oncology were presented at this conference, covering major disease categories including breast cancer, lung cancer, gastrointestinal tumors, urological cancers, and gynecological malignancies. The presentations encompassed several landmark studies with the potential to reshape the landscape of clinical treatment.
Forward Pharma updated the latest trial in progress of FWD1802, the next-generation orally available, selective estrogen receptor degrader (oral SERD) for treating ER+/HER2- breast cancer, at the ESMO 2025 Annual Meeting.
The 2025 ESMO served as a pivotal platform for Chinese innovative pharmaceutical companies to demonstrate their R&D capabilities. The publication of high-quality data stands as a cornerstone for international licensing collaborations.
FWD1802 is anticipated to initiate the pivotal studies. Forward Pharma is committed to strengthening comprehensive collaboration with global partners to accelerate clinical development and product commercialization, thereby bringing clinical benefits to breast cancer patients worldwide.
About ESMO
The European Society for Medical Oncology (ESMO) is Europe's leading professional organization in medical oncology. As an academic institution with over 45,000 members worldwide, ESMO has become a key benchmark for oncology education and information dissemination.
Founded in 1975, ESMO is based in Europe with a global reach. Serving as a platform for all oncology professionals, ESMO brings together healthcare practitioners from diverse specialties. Grounded in the expertise of medical oncology, the organization promotes a multidisciplinary approach to comprehensive cancer care through educational resources and information sharing.
ESMO is committed to eliminating geographical and professional barriers in cancer diagnosis and treatment, continuously advancing its mission in the global oncology field.
About Forward Pharmaceuticals
Forward Pharmaceuticals is an innovative biopharmaceutical company with an independent R&D pipeline spanning target validation, drug discovery, early-stage development, translational medicine research, preclinical studies, clinical development, and regulatory affairs. The company has established international R&D and operational teams in Nanshan District, Shenzhen; Pudong, Shanghai; and Optics Valley, Wuhan. Forward Pharmaceuticals has established proprietary drug discovery platforms with core intellectual property rights and a distinctive drug R&D innovation system since its inception. Building upon this foundation, the company has developed a product pipeline matrix featuring over 10 innovative drugs, with indications spanning multiple solid tumors and autoimmune diseases.